

The genetics of drug-related movement disorders (DRMD), reply to comment: Antipsychotic-induced catatonia and neuroleptic malignant syndrome: The dark side of the moon

Citation for published version (APA):

van der Burg, N. C., Al Hadithy, A. F. Y., van Harten, P. N., van Os, J., & Bakker, P. R. (2021). The genetics of drug-related movement disorders (DRMD), reply to comment: Antipsychotic-induced catatonia and neuroleptic malignant syndrome: The dark side of the moon. *Molecular Psychiatry*, 26(11), 6115-6115. <https://doi.org/10.1038/s41380-021-01212-z>

Document status and date:

Published: 01/11/2021

DOI:

[10.1038/s41380-021-01212-z](https://doi.org/10.1038/s41380-021-01212-z)

Document Version:

Publisher's PDF, also known as Version of record

Document license:

Taverne

Please check the document version of this publication:

- A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
- The final author version and the galley proof are versions of the publication after peer review.
- The final published version features the final layout of the paper including the volume, issue and page numbers.

[Link to publication](#)

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:

www.umlib.nl/taverne-license

Take down policy

If you believe that this document breaches copyright please contact us at:

repository@maastrichtuniversity.nl

providing details and we will investigate your claim.

Download date: 10 Dec. 2024

COMMENT



The genetics of drug-related movement disorders (DRMD), reply to comment: Antipsychotic-induced catatonia and neuroleptic malignant syndrome: The dark side of the moon

Nadine C. van der Burg¹✉, Asmar F. Y. Al Hadithy², Peter N. van Harten^{1,3}, Jim van Os^{3,4,5} and P. Roberto Bakker^{3,4,6}

© The Author(s), under exclusive licence to Springer Nature Limited 2021

Molecular Psychiatry (2021) 26:6115; <https://doi.org/10.1038/s41380-021-01212-z>

TO THE EDITOR:

We thank Dusan Hirjak et al. for their comments and compliments on our paper *The genetics of drug-related movement disorders, an umbrella review of meta-analyses*. They suggest that antipsychotic-related catatonic symptoms (ACS) and neuroleptic malignant syndrome (NMS) should have been included in the umbrella review (UR). We find their concern important and would like reply as follows.

Hirjak et al. state that in clinical practice it is often difficult to disentangle genuine catatonia from ACS, given some overlapping signs and symptoms. In our UR, we state that drug-related movement disorders (DRMD) may be involved in the pathophysiology of psychotic disorders. In that view antipsychotics are not the cause but a moderating factor and may increase the risk of motor dysfunctions. E.g. motor dysfunctions are found in a proportion of antipsychotic-naïve patients, with first-episode schizophrenia and that subgroup is extra vulnerable for drug-induced movement disorders [1–4]. It could be that the same counts for catatonia, i.e. subclinical genuine catatonia may be involved in the pathophysiology of psychotic disorders (and other psychiatric disorders) and ACS could be, partly, an aggravated form of underlying genuine catatonia. Also, malignant catatonia is hard to distinguish from NMS. In both syndromes, antipsychotic treatment plays an important role but in different ways: antipsychotics initiate NMS but aggravate malignant catatonia [5].

Recent genetic studies [6, 7] reveal patterns of shared and distinct gene-expression alterations across psychiatric disorders and the data suggest that common polygenic variation underlies a substantial proportion of cross-disorder expression overlap [8]. The similarities and the possible differences in genetics may suggest a neuropathological and pathophysiological overlap in the background of the syndromes like ACS, NMS, catatonia, and DRMD. Consequently, we propose further genetic research in ACS and NMS to answer the questions raised by Hirjak et al. and by us. However, genetic research into ACS and NMS could be problematic as these phenomena are rare phenotypes.

In summary, we agree that ACS, genuine catatonia, and NMS should be included in a genetic UR on DRMD. Additional genetic research is, however, needed. Therefore, we suggest an update of

our UR when genetic research has been broadened on ACS and NMS.

REFERENCES

1. Ayehu M, Shibre T, Milkias B, Fekadu A. Movement disorders in neuroleptic-naïve patients with schizophrenia spectrum disorders. *BMC Psychiatry*. 2014;14:280.
2. Kasten M, Bruggeman N, Konig IR, Doerry I, Steinlechner S, Wenzel L, et al. Risk for antipsychotic-induced extrapyramidal symptoms: influence of family history and genetic susceptibility. *Psychopharmacology*. 2011;214:729–36.
3. Koning JP, Tenback DE, van Os J, Aleman A, Kahn RS, van Harten PN. Dyskinesia and parkinsonism in antipsychotic-naïve patients with schizophrenia, first-degree relatives and healthy controls: a meta-analysis. *Schizophr Bull*. 2010;36:723–31.
4. Lencer R, Eismann G, Kasten M, Kabakci K, Geithe V, Grimm J, et al. Family history of primary movement disorders as a predictor for neuroleptic-induced extrapyramidal symptoms. *Br J Psychiatry*. 2004;185:465–71.
5. Mann SC, Caroff SN, Keck PE, Lazarus A. Neuroleptic malignant syndrome and related conditions, Second Edition 2003
6. Gandal MJ, Haney JR, Parikshak NN, Leppa V, Ramaswami G, Hartl C, et al. Shared molecular neuropathology across major psychiatric disorders parallels polygenic overlap. *Science*. 2018;359:693–7.
7. Hoehe MR, Morris-Rosendahl DJ. The role of genetics and genomics in clinical psychiatry. *Dialogues Clin Neurosci*. 2018;20:169–77. <https://doi.org/10.31887/DCNS.2018.20.3/mhoehe>.
8. Kendler KS. What psychiatric genetics has taught us about the nature of psychiatric illness and what is left to learn. *Mol Psychiatry*. 2013;18:1058–66.

COMPETING INTERESTS

The authors declare no competing interests.

ADDITIONAL INFORMATION

Correspondence and requests for materials should be addressed to N.C.v.d.B.

Reprints and permission information is available at <http://www.nature.com/reprints>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

¹Zon & Schild, GGZ Centraal, Amersfoort, The Netherlands. ²Scheldezoo Pharmacy, 's Gravenpolder, The Netherlands. ³Department of Psychiatry and Psychology, School for Mental Health and Neuroscience (MHeNS), Maastricht University Medical Centre, Maastricht, The Netherlands. ⁴Department Psychiatry, Brain Centre Rudolf Magnus, Utrecht University Medical Centre, Utrecht, The Netherlands. ⁵King's College London, King's Health Partners Department of Psychosis Studies, Institute of Psychiatry, London, UK. ⁶Psychiatry at Arkin, Amsterdam, The Netherlands. ✉email: nadinevanderburg@yahoo.com

Received: 22 May 2021 Revised: 29 May 2021 Accepted: 23 June 2021
Published online: 9 July 2021